FDA statements, warning letters, compounding guidance, enforcement actions, and Eli Lilly announcements — tracked and contextualized for the retatrutide community.
Following TRIUMPH-1 Phase 3 topline results showing up to 28.3% mean weight loss at 80 weeks, Eli Lilly announced plans to submit a New Drug Application (NDA) to the FDA in Q1 2027. The NDA has not yet been submitted. FDA approval and commercial availability are not guaranteed and depend on the full regulatory review process.
Eli Lilly announced topline results from the TRIUMPH-Obesity Phase 3 trial. Participants treated with retatrutide 12 mg achieved a mean body weight reduction of 22.1% at 48 weeks versus 2.4% for placebo (p<0.001). All primary and key secondary endpoints were met.
Eli Lilly presented interim data from the TRIUMPH-T2D Phase 3 trial at the American Diabetes Association Scientific Sessions. Retatrutide 12 mg reduced HbA1c by a mean of 2.1 percentage points from baseline at 52 weeks versus 0.3% for placebo. Mean body weight reduction was 16.8% in the 12 mg arm.
The FDA has stated that retatrutide cannot be used in compounding under federal law. Retatrutide is not a component of an FDA-approved drug and is not eligible under applicable bulk-substance requirements for 503A or 503B compounding. Any compounded retatrutide is not FDA-authorized.
The FDA issued a warning letter to a Florida-based online pharmacy for marketing and distributing unapproved injectable products labeled as retatrutide. The letter cited violations of the Federal Food, Drug, and Cosmetic Act, including distribution of an unapproved new drug and misbranding.
The Drug Enforcement Administration announced a review of the scheduling status of several research peptides sold online, including some marketed as GLP-1 receptor agonists. The review does not currently include retatrutide but signals increased federal scrutiny of the grey-market peptide supply chain.
The Federal Trade Commission sent warning letters to 15 telehealth platforms and online pharmacies making unsubstantiated weight loss claims for unapproved injectable peptides, including products marketed as retatrutide analogues. The FTC warned that such claims may violate Section 5 of the FTC Act.
The FDA granted Breakthrough Therapy Designation to retatrutide for the treatment of non-alcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH), with fibrosis. The designation is intended to expedite development and review of drugs for serious conditions.
TryTrutide is an independent publication. We are not affiliated with the FDA, Eli Lilly, or any regulatory agency. Items are sourced from public records and official press releases.
No. As of September 2026, retatrutide is not approved by the FDA for any indication. It remains an investigational drug in Phase 3 clinical development under the TRIUMPH program. FDA approval requires successful Phase 3 trial completion, a regulatory submission, and FDA review.
No. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under sections 503A or 503B. It has no approved NDA, is not on any FDA shortage list, and does not appear on the 503B bulk drug substance list.
Following TRIUMPH-1 topline results (May 21, 2026), Eli Lilly announced plans for a Q1 2027 regulatory submission to the FDA. Standard FDA review takes approximately 10–12 months from acceptance; Priority Review (if granted) takes approximately 6 months. Approval and commercial availability are not guaranteed.
No legitimate pharmaceutical-grade retatrutide is available for purchase online. Products sold as "retatrutide" by research chemical vendors are not pharmaceutical-grade, are not sterile, and are not authorized for human use. Purchasing or using such products carries serious legal and health risks.
